Royalty Pharma (RPRX) PT Lowered to $44 at Morgan Stanley
Tweet
Share
E-mailGet Alerts RPRX Hot Sheet
Price: $58.60 +0.07%
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Morgan Stanley analyst Terence Flynn lowered the price target on Royalty Pharma (NASDAQ: RPRX) to $44.00 (from $46.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Va Tech Wabag Ltd. (VATW:IN) PT Raised to INR2,410 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
